Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Telik Announces New TRAP Drug Discovery Agreement
Nov 12, 2008 04:05 PM
- Telik Announces Financial Results for 2008 Third Quarter
Nov 05, 2008 04:05 PM
- Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
Oct 29, 2008 05:05 PM
- Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
Oct 22, 2008 04:05 PM
- Telik Announces Receipt of Nasdaq Notice
Sep 25, 2008 04:06 PM
- Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
Sep 17, 2008 04:05 PM
- Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
Aug 21, 2008 04:05 PM
- Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Aug 21, 2008 04:05 PM
- Telik Announces Diabetes License Agreement With ReceptorBio
Aug 19, 2008 08:02 AM
- ReceptorBio Announces Diabetes License Agreement With Telik
Aug 19, 2008 08:02 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
TELK
|
Compare to S&P
|
| YTD |
-93.95 %
|
-0.01 %
|
| 4 Weeks |
-8.30 %
|
8.57 %
|
| 12 Weeks |
-67.44 %
|
-49.43 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 46.15 %
|
|
EPS Growth in Last Year: 36.36 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
|
